Last reviewed · How we verify
DisperSol Technologies, LLC — Portfolio Competitive Intelligence Brief
2 marketed
0 filed
0 Phase 3
1 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Exjade | Exjade | marketed | Flavin reductase (NADPH), Lysine-specific demethylase 5A | Other | ||
| Jadenu | Jadenu | marketed | Other |
Therapeutic area mix
- Other · 2
- Diabetes · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- ADvantage Therapeutics · 1 shared drug class
- AJU Pharm Co., Ltd. · 1 shared drug class
- AO GENERIUM · 1 shared drug class
- Abbott · 1 shared drug class
- AceLink Therapeutics, Inc. · 1 shared drug class
- Ache Laboratorios Farmaceuticos S.A. · 1 shared drug class
- Aciex Therapeutics, Inc. · 1 shared drug class
- 3D Medicines (Beijing) Co., Ltd. · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for DisperSol Technologies, LLC:
- DisperSol Technologies, LLC pipeline updates — RSS
- DisperSol Technologies, LLC pipeline updates — Atom
- DisperSol Technologies, LLC pipeline updates — JSON
Cite this brief
Drug Landscape (2026). DisperSol Technologies, LLC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/dispersol-technologies-llc. Accessed 2026-06-10.